$219 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 4 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARCELLX INC. | $103,235,000 | +3.8% | 5,500,007 | 0.0% | 47.19% | -3.0% | ||
DSGN | DESIGN THERAPEUTICS INC | $94,075,000 | +19.4% | 5,626,476 | 0.0% | 43.01% | +11.6% | |
NKTX | NKARTA INC. | $17,547,000 | +6.8% | 1,333,333 | 0.0% | 8.02% | -0.2% | |
EFFECTOR THERAPEUTICS INC | $3,889,000 | -59.9% | 6,822,114 | 0.0% | 1.78% | -62.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
ARCELLX INC. | 7 | Q3 2023 | 72.6% |
NKARTA INC. | 6 | Q3 2023 | 8.0% |
ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-12 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-10 |
13F-HR/A | 2023-05-19 |
13F-HR | 2023-05-09 |
13F-HR | 2023-02-08 |
13F-HR | 2022-11-08 |
13F-HR | 2022-08-02 |
13F-HR | 2022-05-10 |
13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.